NEUROMETRIX, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2020-12-31: Form 8-K; Period of report 2020-12-30; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2020-10-22: Form 8-K; Period of report 2020-10-22; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2020-07-23: Form 8-K; Period of report 2020-07-23; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2020-06-11: Form 8-K; Period of report 2020-06-11; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2020-12-31 | 8-K | 2020-12-30 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 30, 2020, the Compensation Committee of the Board of Directors of NeuroMetrix, Inc. (the “Company”) approved new employment agreements for Shai N. Gozani, M.D., Ph.D., President and Chief Executive Officer of the Company and Thomas T. Higgins, Senior Vice President and Chief Financial Officer of the Company. | a20201231-form8xkexecutive.htm |
| 2020-10-22 | 8-K | 2020-10-22 | 2.02 Results of Operations and Financial Condition | 2.02 On October 22, 2020, NeuroMetrix, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2020. | a20200930-form8xkq3earning.htm |
| 2020-07-23 | 8-K | 2020-07-23 | 2.02 Results of Operations and Financial Condition | 2.02 On July 23, 2020, NeuroMetrix, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2020. | a20200630-form8xkq2earning.htm |
| 2020-06-11 | 8-K | 2020-06-11 | 8.01 Other Events | 8.01 On June 11, 2020, NeuroMetrix, Inc. (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) with the Securities and Exchange Commission (the “Commission”) to register the offer and sale of $113,000 of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) pursuant to the Company’s effective “shelf” registration statement on Form S-3 and an accompanying base prospectus contained therein (Registration Statement No. 333-229349) filed with the Commission on January 24, 2019, and declared effective on March 8, 2019 (together with the Prospectus Supplement, the “Prospectus”). | neurometrix-form8xkrefilin.htm |
| 2020-06-05 | 8-K | 2020-06-05 | 8.01 Other Events | 8.01 On June 5, 2020, NeuroMetrix, Inc. (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) with the Securities and Exchange Commission (the “Commission”) to register the offer and sale of $184,000 of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) pursuant to the Company’s effective “shelf” registration statement on Form S-3 and an accompanying base prospectus contained therein (Registration Statement No. 333-229349) filed with the Commission on January 24, 2019, and declared effective on March 8, 2019 (together with the Prospectus Supplement, the “Prospectus”). | neurometrix-form8xkrefilin.htm |
| 2020-06-01 | 8-K | 2020-06-01 | 8.01 Other Events | 8.01 On June 1, 2020, NeuroMetrix, Inc. (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) with the Securities and Exchange Commission (the “Commission”) to register the offer and sale of $315,000 of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) pursuant to the Company’s effective “shelf” registration statement on Form S-3 and an accompanying base prospectus contained therein (Registration Statement No. 333-229349) filed with the Commission on January 24, 2019, and declared effective on March 8, 2019 (together with the Prospectus Supplement, the “Prospectus”). | neurometrix-form8xkrefilin.htm |
| 2020-05-20 | 8-K | 2020-05-20 | 8.01 Other Events | 8.01 On May 20, 2020, NeuroMetrix, Inc. (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) with the Securities and Exchange Commission (the “Commission”) to register the offer and sale of $570,000 of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) pursuant to the Company’s effective “shelf” registration statement on Form S-3 and an accompanying base prospectus contained therein (Registration Statement No. 333-229349) filed with the Commission on January 24, 2019, and declared effective on March 8, 2019 (together with the Prospectus Supplement, the “Prospectus”). | neurometrix-form8xkrefilin.htm |
| 2020-05-07 | 8-K | 2020-05-06 | 8.01 Other Events | 8.01 As previously disclosed, on April 28, 2020, NeuroMetrix, Inc. (the “Company”) received a loan of $773,200 (the “Loan”) from Comerica Bank (the “Bank”) under the U.S. Small Business Administration (“SBA”) Paycheck Protection Program (the “PPP”) of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). | neurometrix-form8xkreturno.htm |
| 2020-04-30 | 8-K | 2020-04-30 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Material Definitive Agreement. 2.03 The information disclosed in Item 1.01 above is incorporated herein by reference. | neurometrix-form8xkforpppl.htm |
| 2020-04-28 | 8-K | 2020-04-28 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The NeuroMetrix, Inc. (the “Company”) Annual Meeting of Stockholders was held in a virtual format on April 28, 2020 (the “Annual Meeting”). | neurometrix-form8xkfor2020.htm |
| 2020-04-24 | 8-K | 2020-04-24 | 8.01 Other Events | 8.01 On April 24, 2020, NeuroMetrix, Inc. (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) with the Securities and Exchange Commission (the “Commission”) to register the offer and sale of $1,100,000 of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) pursuant to the Company’s effective “shelf” registration statement on Form S-3 and an accompanying base prospectus contained therein (Registration Statement No. 333-229349) filed with the Commission on January 24, 2019, and declared effective on March 8, 2019 (together with the Prospectus Supplement, the “Prospectus”). | neurometrix-form8xkrefilin.htm |
| 2020-04-23 | 8-K | 2020-04-23 | 2.02 Results of Operations and Financial Condition | 2.02 On April 23, 2020, NeuroMetrix, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2020. | a20200331-form8xkq1earning.htm |
| 2020-03-04 | 8-K | 2020-03-04 | 8.01 Other Events | 8.01 On March 4, 2020, NeuroMetrix, Inc. (the “Company”) reported that it had reached a settlement with the Federal Trade Commission (the “Commission”) of the previously reported investigation initiated in 2017 regarding compliance of the Company’s representations about its Quell® product with Sections 5 and 12 of the Federal Trade Commission Act. | neurometrix-form8xkmarch42.htm |
| 2020-02-19 | 8-K | 2020-02-19 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | neurometrix-form8xkenterin.htm |
| 2020-01-27 | 8-K | 2020-01-27 | 2.02 Results of Operations and Financial Condition | 2.02 On January 27, 2020, NeuroMetrix, Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2019. | neurometrix-form8xkpressre.htm |